{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:46:10Z","timestamp":1791179170820,"version":"4.1.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2012,4,30]]},"DOI":"10.2217\/fon.12.23","type":"journal-article","created":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T13:15:29Z","timestamp":1334841329000},"page":"359-371","source":"Crossref","is-referenced-by-count":7,"title":["Bortezomib: A Proteasome Inhibitor with An Evolving Role in Select Subtypes of B-Cell Non-Hodgkin\u2019s Lymphoma"],"prefix":"10.1080","volume":"8","author":[{"given":"Jamie L","family":"Koprivnikar","sequence":"first","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, 3800 Reservoir Road, NW, Washington, DC20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D","family":"Cheson","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, 3800 Reservoir Road, NW, Washington, DC20007, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2012,4,19]]},"reference":[{"key":"e_1_3_2_3_1_1","unstructured":"Cancer Facts and Figures 2010 . American Cancer Society Atlanta GA USA (2010)."},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2493"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053541"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24004"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"crossref","unstructured":"Rummel M NiederleN MaschmeyerGet al. Bendamustine plus rituximab is superior in respect of progression-free survival and CR rate when compared with CHOP plus rituximab as first-line treatment of patients with advanced follicular indolent and mantle cell lymphoma: final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas Germany). Presented at: 51st ASH Annual Meeting and Exposition. New Orleans LA USA 5\u20138 December 2009 (Abstract 405).","DOI":"10.1182\/blood.V114.22.405.405"},{"key":"e_1_3_2_3_11_1","unstructured":"Velcade \u00ae (bortezomib) for injection prescribing information. Millennium Pharmaceuticals Cambridge MA USA (2006)."},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_3_2_3_13_1","first-page":"2505","article-title":"A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.","volume":"8","author":"Aghajanian C","year":"2002","unstructured":"Aghajanian C , SoignetS, DizonDSet al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8, 2505\u20132511 (2002).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.005710"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04870"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.09.003"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.4079"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22097"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"crossref","unstructured":"Ribrag V TillyH CasasnovasOet al. Final results of a randomized Phase 2 multicenter study of two bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d\u2019Etude Des Lymphomes De l\u2019Adulte (GELA) Study FL-05. Presented at: 52nd ASH Annual Meeting and Exposition. Orlando FL USA 4\u20137 December 2010 (Abtract 768).","DOI":"10.1182\/blood.V116.21.768.768"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07836.x"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1498"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.1142"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08820.x"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.6594"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr450"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7980"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389119525"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1844"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-314708"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.041392"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"crossref","unstructured":"Morrison VA JungS JohnsonJL LeonardJ ChesonBD. A Phase II trial of bortezomib plus lenalidomide for relapsed\/refractory mantle cell lymphoma (MCL) (CALGB 50501).Presented at:2011 ASCO Annual Meeting.Chicago IL USA 3\u20137 June 2011.","DOI":"10.1200\/jco.2011.29.15_suppl.tps223"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70150-4"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"crossref","unstructured":"Coiffier B LiW HenitzEet al. Identification of patient subgroups demonstrating longer progression-free survival (PFS) benefit with bortezomib-rituximab versus rituximab in patients with relapsed or refractory follicular lymphoma (FL): biomarker analyses of the Phase 3 LYM3001 study. Presented at: 2011 ASH Annual Meeting. San Diego CA USA 10\u201313 December 2011.","DOI":"10.1182\/blood.V118.21.265.265"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.030"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001537"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.12.23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:46Z","timestamp":1719125026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.12.23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,19]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4,30]]}},"alternative-id":["10.2217\/fon.12.23"],"URL":"https:\/\/doi.org\/10.2217\/fon.12.23","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,19]]}}}